Estudio comparativo de la vitrectomía asociada o no a la triamcinolona acetónido en el tratamiento del edema macular diabético difuso

Abstract

Objective: To compare the efficiency between the association or not of subtenon triamcinolone acetonide (TAS) as a coadjuvant treatment of vitrectomy (VPP) in patients affected of macular diabetic diffuse edema (EMD). Methods: Randomised retrospective and interventional study of 41 eyes from 29 consecutive patients affected of macular diabetic diffuse edema. All the patients were treated with VPP. After this procedure, all of them were consecutively randomised (1:1) in two groups. Only one group received coadjuvant treatment with a subtenon injection of 40mg of triamcinolone acetonide. Visual Acuity (VA) and macular thickness determined with optical coherence tomography were analyzed. Both variables were measured before and days 1, 3,7, 30 after the treatment. Posteriorly, each three months. Results: 22 patients affected of diffuse EMD were treated with VPP and 19 with VPP + TAS. Mean age was 61 years. VA 6 months after the treatment was VPP=0,17 and VPP + TAS=0,29 whereas macular thickness 6 months after the treatment was VPP=410μm and VPP+TAS= 469μm (p≥0.05). Conclusions: Our results suggest that TAS as a coadjuvant treatment of VPP in patients affected of diffuse EMD is not efficient. Moreover, it is a procedure that may expose the patient to collateral side effects.